Time-restricted eating with or without low-carbohydrate diet reduces visceral fat and improves metabolic syndrome : A randomized trial
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved..
Overconsumption of carbohydrate-rich food combined with adverse eating patterns contributes to the increasing incidence of metabolic syndrome (MetS) in China. Therefore, we conducted a randomized trial to determine the effects of a low-carbohydrate diet (LCD), an 8-h time-restricted eating (TRE) schedule, and their combination on body weight and abdominal fat area (i.e., primary outcomes) and cardiometabolic outcomes in participants with MetS. Compared with baseline, all 3-month treatments significantly reduce body weight and subcutaneous fat area, but only TRE and combination treatment reduce visceral fat area (VFA), fasting blood glucose, uric acid (UA), and dyslipidemia. Furthermore, compared with changes of LCD, TRE and combination treatment further decrease body weight and VFA, while only combination treatment yields more benefits on glycemic control, UA, and dyslipidemia. In conclusion, without change of physical activity, an 8-h TRE with or without LCD can serve as an effective treatment for MetS (ClinicalTrials.gov: NCT04475822).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 3(2022), 10 vom: 18. Okt., Seite 100777 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
He, Mingqian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.10.2022 Date Revised 26.10.2022 published: Print-Electronic ClinicalTrials.gov: NCT04475822 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2022.100777 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347352588 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347352588 | ||
| 003 | DE-627 | ||
| 005 | 20231226033623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2022.100777 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347352588 | ||
| 035 | |a (NLM)36220069 | ||
| 035 | |a (PII)S2666-3791(22)00332-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a He, Mingqian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Time-restricted eating with or without low-carbohydrate diet reduces visceral fat and improves metabolic syndrome |b A randomized trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2022 | ||
| 500 | |a Date Revised 26.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04475822 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Overconsumption of carbohydrate-rich food combined with adverse eating patterns contributes to the increasing incidence of metabolic syndrome (MetS) in China. Therefore, we conducted a randomized trial to determine the effects of a low-carbohydrate diet (LCD), an 8-h time-restricted eating (TRE) schedule, and their combination on body weight and abdominal fat area (i.e., primary outcomes) and cardiometabolic outcomes in participants with MetS. Compared with baseline, all 3-month treatments significantly reduce body weight and subcutaneous fat area, but only TRE and combination treatment reduce visceral fat area (VFA), fasting blood glucose, uric acid (UA), and dyslipidemia. Furthermore, compared with changes of LCD, TRE and combination treatment further decrease body weight and VFA, while only combination treatment yields more benefits on glycemic control, UA, and dyslipidemia. In conclusion, without change of physical activity, an 8-h TRE with or without LCD can serve as an effective treatment for MetS (ClinicalTrials.gov: NCT04475822) | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a abdominal obesity | |
| 650 | 4 | |a low-carbohydrate diet | |
| 650 | 4 | |a metabolic syndrome | |
| 650 | 4 | |a time-restricted eating | |
| 650 | 4 | |a visceral fat area | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Uric Acid |2 NLM | |
| 650 | 7 | |a 268B43MJ25 |2 NLM | |
| 700 | 1 | |a Wang, Jingya |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Deji, Cuomu |e verfasserin |4 aut | |
| 700 | 1 | |a Sui, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ya-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yufeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yixuan |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Buyue |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Huaixi |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Mao |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Shi |e verfasserin |4 aut | |
| 700 | 1 | |a Geng, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Wen-Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Xiaoxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Wen-Zhi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ziyi |e verfasserin |4 aut | |
| 700 | 1 | |a Rensen, Patrick C N |e verfasserin |4 aut | |
| 700 | 1 | |a Hui, Chi-Chung |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanan |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Bingyin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 3(2022), 10 vom: 18. Okt., Seite 100777 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2022 |g number:10 |g day:18 |g month:10 |g pages:100777 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2022.100777 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2022 |e 10 |b 18 |c 10 |h 100777 | ||